Rosenberg Matthew Hamilton Has $42,000 Stock Holdings in CVS Health Corporation $CVS

Rosenberg Matthew Hamilton lifted its holdings in shares of CVS Health Corporation (NYSE:CVS) by 59.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 608 shares of the pharmacy operator’s stock after purchasing an additional 226 shares during the period. Rosenberg Matthew Hamilton’s holdings in CVS Health were worth $42,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in CVS. Goldman Sachs Group Inc. boosted its position in shares of CVS Health by 87.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator’s stock valued at $672,598,000 after purchasing an additional 4,632,530 shares in the last quarter. Dodge & Cox boosted its position in shares of CVS Health by 4.8% during the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after purchasing an additional 3,353,223 shares in the last quarter. Nuveen LLC bought a new stake in shares of CVS Health during the 1st quarter valued at about $204,421,000. Invesco Ltd. boosted its position in shares of CVS Health by 13.2% during the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock valued at $1,383,039,000 after purchasing an additional 2,375,764 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its position in shares of CVS Health by 815.2% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator’s stock valued at $183,701,000 after purchasing an additional 2,372,121 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the transaction, the director directly owned 22,156 shares of the company’s stock, valued at $1,573,519.12. This trade represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.22% of the stock is owned by corporate insiders.

CVS Health Stock Performance

Shares of CVS opened at $81.40 on Friday. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The stock has a 50 day moving average of $73.65 and a 200 day moving average of $68.02. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $81.93. The company has a market capitalization of $103.24 billion, a price-to-earnings ratio of 22.74, a PEG ratio of 0.89 and a beta of 0.60.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.35. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. During the same period last year, the business posted $1.83 earnings per share. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is currently 74.30%.

Analysts Set New Price Targets

CVS has been the topic of several recent research reports. Barclays increased their price target on CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a report on Thursday, September 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $78.00 price objective on shares of CVS Health in a research note on Tuesday, August 26th. Baird R W raised CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Wolfe Research increased their price objective on CVS Health from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of CVS Health in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $81.05.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.